1 ADMINISTRATION INFORMATION

2 **Title**

| 2 | T CC | | | | | | e | .14.1.1. |
|---|---------|--------|-----------|-----------|------------|------------------------|------------|-----------|
| 1 | ETTECTS | or n | aiviaiiai | component | s or remor | e monitoring | i tor im | niantanie |
| 5 | Lincew | or m | uiviuuuu | component | 5 of remot | c momeorm _c | | plantable |

- 4 cardioverter defibrillators or cardiac resynchronisation therapy defibrillators:
- 5 protocol for a systematic review and component network meta-analysis
- 6

7 Registration

- 8 In accordance with the guidelines, our systematic review protocol was registered with
- 9 the International Prospective Register of Systematic Reviews (PROSPERO) on 7 March
- 10 2024 (registration number CRD42024517406).
- 11

12 Authors

13 Makiko Okazaki^{1,2}, Natsuko Sekiguchi³, Yuki Sahashi^{4,5}, Hisashi Noma⁶, Takahiro

14 Mihara¹

- 15
- ¹ Department of Health Data Science, Yokohama City University Graduate School of
- 17 Data Science, Yokohama, Japan
- ¹⁸ ² Department of Clinical Engineering, Sakakibara Heart Institute, Fuchu, Japan
- ¹⁹ ³Division of Nursing, Higashigaoka Faculty of Nursing, Tokyo Healthcare University,
- 20 Meguro, Japan
- ⁴ Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, USA
- ⁵ Department of Cardiology, Gifu University, Gifu, Japan
- ⁶Department of Data Science, The Institute of Statistical Mathematics, Tachikawa,
- 24 Japan

25

- 26 Corresponding author: Takahiro Mihara
- 27 Department of Health Data Science, Yokohama City University Graduate School of
- 28 Data Science, Yokohama 236-0027, Japan
- 29 Phone number: +81-45-787-2800
- 30 E-mail: meta.analysis.r@gmail.com
- 31

32 Funding

- 33 This research did not receive any specific grants from funding agencies in the public,
- 34 commercial, or not-for-profit sectors.
- 35
- 36 Conflict of interest statement
- 37 None declared.
- 38

39 ABSTRACT

40

| 41 | Introduction: Currently, the standard of care for patients with cardiac implantable |
|----|--|
| 42 | electronic devices (CIEDs) such as implantable cardioverter-defibrillators (ICD) and |
| 43 | cardiac resynchronisation therapy-defibrillators (CRT-D) involves a combination of |
| 44 | in-person outpatient visits and remote monitoring (RM). RM consists of scheduled |
| 45 | remote device interrogation and automated transmission of prespecified alerts (alert |
| 46 | transmission) at varying frequencies depending on manufacturers and institutions. |
| 47 | However, the effects of RM factors on prognosis remain unclear. This systematic review |
| 48 | and component network meta-analysis (CNMA) will aim to investigate which RM |
| 49 | components (device interrogation, alert transmission, and data transmission frequency) |
| 50 | have the greatest impact on prognosis in patients with ICD or CRT-D. |
| 51 | Methods and analysis: A systematic review will be conducted using MEDLINE |
| 52 | (PubMed), Embase, the Cochrane Central Register of Controlled Trials, the Web of |
| 53 | Science, Clinical Trials.gov, the WHO International Clinical Trials Registry Platform |
| 54 | (ICTRP), the European Union Clinical Trials Register (EU-CTR), and the University |
| 55 | Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR). We will |
| 56 | include randomised controlled trials (RCTs) assessing the effect of RM on patient |
| 57 | outcomes in individuals with ICD or CRT-D. The primary outcome will be |
| 58 | hospitalisation due to cardiovascular disease, heart failure, and device-related |
| 59 | complications. Two authors will independently conduct literature screening, data |
| 60 | extraction, and risk of bias assessment. Random-effects model pairwise meta-analysis, |
| 61 | random-effects network meta-analysis (NMA), and additive CNMA will be applied in |
| 62 | data synthesis. To assess the quality of evidence, we will employ the Grading of |

- 63 Recommendations Assessment, Development, and Evaluation (GRADE) approach for
- 64 pairwise meta-analysis and the Confidence in Network Meta-Analysis (CINeMA)
- 65 approach for NMA.
- 66 Ethics and dissemination: Ethics approval is not required as this study will use
- 67 existing published data. The results will be submitted for publication in a peer-reviewed
- 68 journal.
- 69 **PROSPERO registration number**: CRD42024517406.
- 70
- 71 Keywords: Remote Monitoring; Defibrillators, Implantable; Cardiac Resynchronisation
- 72 Therapy Devices; Network Meta-Analysis; Outpatients; Hospitalization; Randomized
- 73 Controlled Trials
- 74

75 INTRODUCTION

76

77 Rationale

- 78 Implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation
- 79 therapy-defibrillator (CRT-D) implantation improves cardiac function and prevents
- sudden arrhythmic death [1, 2]. The current post-implantation standard of care involves
- 81 a combination of in-person outpatient visits and remote monitoring (RM) [3, 4]. To date,
- 82 several studies have examined the safety and efficacy of RM [4-6] and reported that RM
- 83 reduces the number of in-person outpatient visits without compromising safety [5],

84 decreases all-cause mortality [6], and reduces emergency clinic visits in patients with

85 heart failure and ICD or CRT-D implants [7]. These studies have predominantly

86 compared RM with conventional in-person outpatient care.

87 RM involves scheduled remote device interrogation and automated transmission of

88 prespecified alerts (alert transmission) [8]. Furthermore, the frequency of remote data

89 transmission varies depending on the manufacturers and institutions involved in

90 reported studies [9]. The combination of in-person outpatient visits, scheduled remote

91 device interrogation, and alert transmission demands substantial staff time [10].

92 Therefore, identifying which of these RM components have the greatest impact on

93 patient outcomes is crucial to understanding which component should be prioritised in

94 patient management. However, the effects of RM components on outcomes and patient

95 management remain unclear.

96 Component network meta-analysis (CNMA) allows the estimation of the individual

97 effects of multiple components within complex interventions [11]. Therefore, the study

98 will utilise CNMA to elucidate the relative effects of remote device interrogation, alert

- 99 transmission, and data transmission frequency on patient outcomes.
- 100
- 101 **Objectives**
- 102 The objective of this systematic review will be to evaluate which components of RM
- 103 have the greatest impact on prognosis in patients with ICD or CRT-D.
- 104
- 105 METHODS
- 106

107 Study design

- 108 The study will be a systematic review incorporating CNMA. This protocol follows the
- 109 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
- 110 (PRISMA-P) guidelines [12]. The systematic review will be reported using the PRISMA
- 111 guidelines extension for systematic reviews incorporating network meta-analyses of
- 112 health care interventions (PRISMA-NMA) [13] to structure the contents of the final
- 113 report. We will conduct CNMA according to PRISMA-NMA guidelines and the
- 114 Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [13, 14]. This
- 115 protocol has been registered with the International Prospective Register of Systematic
- 116 Reviews (PROSPERO) (registration number: CRD42024517406).
- 117

118 Eligibility criteria

- 119 We will include randomised controlled trials (RCTs), including re-analyses of
- 120 previously published RCTs that did not originally include the outcomes covered by this
- 121 study. We will exclude quasi-experimental studies.
- 122

123 Participants

- 124 We will include studies examining patients who underwent ICD or CRT-D implantation
- 125 and studies involving other cardiac implantable electronic devices (CIEDs) if ICD or
- 126 CRT-D data are reported separately.
- 127

128 Interventions

- 129 RM involving data transmission without in-person interaction will be included. RM will
- 130 comprise scheduled interrogation and alert transmission. Moreover, scheduled
- 131 interrogations will be classified as daily or interval interrogations as described by the
- 132 device manufacturer. Thus, in CNMA intervention components will be classified as
- 133 daily remote interrogation, interval remote interrogation, or alert transmission.
- 134
- 135 Comparators
- 136 Conventional in-person outpatient visits will be the reference component as these are
- 137 the most common comparators reported in published studies and are routinely
- 138 performed in clinical practice.
- 139

140 Outcomes

- 141 Studies including at least one of the following outcomes are eligible including outcomes
- 142 reported as a component of a composite outcome:
- 143 · hospitalisation (cardiovascular, heart failure, device-related)
- 144 · mortality (all-cause, cardiovascular)
- 145 unscheduled outpatient visits
- 146 unscheduled hospitalisation

147

- 148 Timing
- 149 No restrictions on follow-up periods will be applied.
- 150
- 151 Setting
- 152 No restrictions on setting will be applied.
- 153
- 154 Language
- 155 We will not impose language restrictions in our literature searches.

156

157 Information sources

- 158 We will use MEDLINE (PubMed), Embase, the Cochrane Central Register of
- 159 Controlled Trials, and the Web of Science. The reference lists of the relevant articles
- 160 will also be searched. Further, we will conduct searches via Clinical Trials.gov, the

161 WHO International Clinical Trials Registry Platform (ICTRP), the European Union

162 Clinical Trials Register (EU-CTR), and the University Hospital Medical Information

163 Network Clinical Trials Registry (UMIN-CTR).

164

165 Search strategy

- 166 Search strategies will be developed using medical subject headings (MeSH) and free
- 167 text words relating to ICD, CRT-D, and RM. The proposed search strategy for
- 168 MEDLINE is presented in Table 1. Search strategies for other databases, registries, and
- 169 websites are explained in Supplementary File 1.
- 170

171 Table 1 Search strategy for PubMed

| Number | Search terms |
|--------|---|
| #1 | "defibrillators, implantable"[MeSH Terms] OR |
| | ("implantable"[Title/Abstract] AND "cardioverter*"[Title/Abstract]) OR |
| | ("implantable"[Title/Abstract] AND "defibrillator*"[Title/Abstract]) OR |
| | ("implantable"[Title/Abstract] AND "cardioverter"[Title/Abstract] AND |
| | "defibrillator*"[Title/Abstract]) OR "cardiac resynchronization therapy |
| | devices"[MeSH Terms] OR ("cardiac"[Title/Abstract] AND |
| | "resynchronization"[Title/Abstract]) OR ("cardiac"[Title/Abstract] AND |
| | "resynchronisation"[Title/Abstract]) OR |
| | ("resynchronization"[Title/Abstract] AND "therapy"[Title/Abstract]) OR |
| | ("resynchronisation"[Title/Abstract] AND "therapy"[Title/Abstract]) OR |
| | ("resynchronization"[Title/Abstract] AND "device*"[Title/Abstract]) OR |
| | ("resynchronisation"[Title/Abstract] AND "device*"[Title/Abstract]) OR |
| | "biventricular"[Title/Abstract] OR "CIED*"[Title/Abstract] OR |
| | ("biventricular"[Title/Abstract] AND "implantable"[Title/Abstract] AND |
| | "cardioverter"[Title/Abstract] AND "defibrillator*"[Title/Abstract]) OR |
| | ("cardiac"[Title/Abstract] AND "implantable"[Title/Abstract] AND |
| | "electronic"[Title/Abstract] AND "device*"[Title/Abstract]) |
| #2 | ("remote"[Title/Abstract] AND "monitor*"[Title/Abstract]) OR |
| | ("remote"[Title/Abstract] AND "manag*"[Title/Abstract]) OR |
| | ("remote"[Title/Abstract] AND "follow up"[Title/Abstract]) OR |
| | ("remote"[Title/Abstract] AND "transmission"[Title/Abstract]) OR |

| | ("wireless"[Title/Abstract] AND "monitor*"[Title/Abstract]) OR |
|----|--|
| | ("wireless"[Title/Abstract] AND "manag*"[Title/Abstract]) OR |
| | ("wireless"[Title/Abstract] AND "follow up"[Title/Abstract]) OR |
| | ("wireless"[Title/Abstract] AND "transmission"[Title/Abstract]) OR |
| | "homemonitor*"[Title/Abstract] OR |
| | "remotemanagement"[Title/Abstract] OR "home |
| | monitor*"[Title/Abstract] OR "telemonitor*"[Title/Abstract] OR |
| | "Telemetry"[MeSH Terms] OR "Telemetry"[Title/Abstract] OR |
| | "telemedicine"[MeSH Terms] OR "telemedicine"[Title/Abstract] |
| #3 | ("randomized controlled trial"[Publication Type] OR "controlled clinical |
| | trial"[Publication Type] OR "randomized"[Title/Abstract] OR |
| | "placebo"[Title/Abstract] OR "drug therapy"[MeSH Subheading] OR |
| | "randomly"[Title/Abstract] OR "trial"[Title/Abstract] OR |
| | "groups"[Title/Abstract]) NOT ("animals"[MeSH Terms] NOT |
| | "humans"[MeSH Terms]) |
| #4 | #1 AND #2 AND #3 |
| | |

172

173 Study records

- 174 Data management
- 175 Database citations will be exported using Mendeley Reference Manager
- 176 (https://www.mendeley.com/reference-management/reference-manager; Elsevier,
- 177 Amsterdam, Netherlands). The search results will be uploaded to Rayyan
- 178 (http://rayyan.qcri.org; Rayyan Systems, Cambridge, MA, USA), a free web and mobile
- 179 application that facilitates abstract and title screening and collaboration among

180 reviewers [15].

181

- 182 Study selection
- 183 Two reviewers will independently screen the titles and abstracts of each study identified
- 184 using the described search strategies. We will retrieve the full texts of studies that
- appear to meet the eligibility criteria and those of which eligibility is questioned.
- 186 Disagreements between reviewers will be resolved through discussion.
- 187
- 188 Data collection process
- 189 Two reviewers will independently extract data in duplicate from each eligible study. To
- 190 ensure consistency between reviewers, the first 5 titles will be screened via a data
- 191 collection form and discussion. Discrepancies will be resolved via discussion (including
- 192 a third reviewer if necessary). If data are missing or presented ambiguously, we will
- 193 contact the study authors for clarification.
- 194

195 Data items

- 196 A data collection sheet will be created. The following data will be extracted:
- 197 1. patient characteristics (age, sex, device type, New York Heart Association
- 198 functional class, underlying heart disease, and left ventricular ejection fraction)
- 199 2. intervention and control details (RM interrogation schedule, in-person outpatient200 visit timing, and alert transmission criteria)
- 201 3. outcome data (including mortality, hospitalisation, and dropout rate)
- 4. study details (title, author information, year of publication, trial design, trial size,
- 203 eligibility criteria, exclusion criteria, duration of follow-up, type and source of

- financial support, study settings, and publication status)
- 205 Values, for example, means, will be approximated from figures if necessary.
- 206
- 207 Outcomes and prioritisation
- 208 Primary outcome
- 209 Hospitalisation including cardiovascular, heart failure, and device-related
- 210 hospitalisation.
- 211
- 212 Secondary outcomes
- 213 All-cause mortality, cardiovascular mortality, unscheduled outpatient visits, and
- 214 unscheduled hospitalisation.
- 215
- 216 If outcomes are reported as a composite endpoint, we will extract individual outcomes
- 217 of interest from study results if extractable. If not extractable, we will contact the study
- authors for clarification.
- 219

220 Risk of bias in individual studies

- 221 Two reviewers will independently assess the risk of bias, and disagreement will be
- 222 resolved through discussion. The revised Cochrane risk-of-bias tool for RCTs (RoB 2.0;
- cochrane.org) [16] will be used. The tool assesses bias across 5 domains, and the overall
- risk of bias is determined based on the results of these domains:
- 225 1. Bias arising from the randomisation process
- 226 2. Bias due to deviations from intended interventions
- 227 3. Bias due to missing outcome data

- 228 4. Bias in the measurement of outcomes
- 229 5. Bias for selection of the reported result
- Each domain's risk of bias and overall risk of bias will be described as "low," "some
- concern," or "high."
- 232

233 Data synthesis and analysis

- 234 Summary measures (measures of treatment effect)
- 235 Dichotomous outcomes such as hospitalisation and mortality will be analysed using risk
- ratio (RR) with 95% confidence intervals (CI). Continuous outcomes will be analysed
- 237 using mean difference (MD) or standardised mean difference (SMD) if different
- 238 measurement scales are used with 95% CI. If data is missing, we will contact the
- authors of the study to obtain the relevant missing data.
- 240
- 241 Pairwise meta-analysis
- 242 If multiple studies with conventional in-person outpatient visits as a comparator are
- 243 identified, we will conduct pairwise meta-analyses to assess the effectiveness of RM
- intervention for each outcome. We will use the DerSimonian and Laird [17]
- 245 meta-analysis with random effects method to combine the results and present summary
- 246 measures alongside the estimated effects of each study using forest plots. Heterogeneity
- 247 will be quantified using I^2 statistics.

- 249 Network meta-analysis
- 250 *Review of network geometry*
- 251 We will construct a network diagram and evaluate the network geometry [13].

252 Evaluating the geometry of the network allows for an assessment of the feasibility of

- 253 NMA, such as determining whether the network of interventions is connected.
- Additionally, this assessment includes the identification of closed loops of treatments
- 255 within the network, facilitating the evaluation of inconsistency that is the disagreement
- 256 between effects estimated from direct and indirect sources.
- 257
- 258 Transitivity and inconsistency in NMA
- 259 We will statistically evaluate both local and global inconsistency. The local assessment
- will be performed using the side-splitting method [18] while the global assessment will
- 261 be conducted via the design-by-treatment interaction model [19].
- 262 We will perform a random-effects NMA assuming a common between-studies
- 263 variance across the whole network. Summary effect measures such as RR will be
- estimated along with 95% CI. The results of the estimation will be presented using the
- league table and the Surface Under the Cumulative Ranking curve (SUCRA) [20]. We
- will use the R package "nma" (cran.r-project.org/web/packages/NMA/index.html) [21].

- 268 Component network meta-analysis
- 269 Additivity assumption in CNMA
- 270 CNMA allows the estimation of component effects of multicomponent interventions. In
- this context, an additivity assumption is used, which means that the effect of each
- intervention can be expressed as the sum of the effects of its individual components. We
- 273 will use the method based on a comparison of treatment estimates from the standard
- NMA and the additive CNMA model to assess the additivity assumption [11, 22].
- 275 If additivity holds, we will use an additive effects-based CNMA model for estimating

| 276 | the relative effects of com | ponents. The res | ults of the estin | mation will be | presented | using |
|-----|-----------------------------|------------------|-------------------|----------------|-----------|-------|
| | | | | | | |

- the league table and the P-score, a frequentist version of SUCRA [23]. We will use the
- 278 R package "netmeta" (cran.r-project.org/web/packages/netmeta/index.html) [24].

279

280 Narrative synthesis

- 281 If quantitative synthesis is not feasible due to significant between-studies heterogeneity
- 282 or an insufficient number of studies, we will conduct systematic narrative synthesis.
- 283 This approach will use information from the text and tables to summarise and describe
- the characteristics and findings of the included studies.

285

- 286 Additional analyses
- 287 Sensitivity analysis
- 288 To assess the robustness of our findings based on the primary analysis, we plan to
- 289 perform a sensitivity analysis after excluding studies with a high risk of bias.

290

- 291 Subgroup analysis
- 292 We will conduct a subgroup analysis classified by device type (ICD or CRT-D) to
- examine the consistency of results and validate the robustness of our findings.

294

- 295 Statistical analyses will be performed using the latest versions of R software (R
- 296 Foundation for Statistical Computing, Vienna, Austria) [25] and RStudio (RStudio,
- Boston, MA, USA) [26] at the time of analysis.

298

299 Risk of bias across studies

300 If a study protocol is available, we will compare outcomes reported in the protocol or 301 trial registry with those in the published studies to assess the potential risk of reporting 302 bias. Small study effects will be assessed using Egger's regression to detect funnel plot 303 asymmetry [27] using a significance threshold of p<0.1.

304

305 Confidence in cumulative estimate

- 306 We will use the Grading of Recommendations Assessment, Development, and
- 307 Evaluation (GRADE) approach to assess the certainty of evidence for each outcome in
- 308 pairwise meta-analyses [28]. The quality of evidence will be assessed across the
- 309 following domains: limitations in study design, risk of bias, inconsistency, indirectness,
- 310 imprecision of the results, and publication bias. The quality of evidence will be
- 311 categorised as high, moderate, low, or very low. The Confidence in Network
- 312 Meta-Analysis (CINeMA) approach will be used to evaluate confidence in the NMA
- 313 estimates [29-31].
- 314

315 IMPLICATION AND LIMITATION

316 In the proposed study, we will aim to estimate the effect size of each RM component on

317 patient outcomes. The current follow-up practices for CIEDs, including ICDs and

- 318 CRT-Ds, recommend RM [3,4] based on known benefits including reductions in
- all-cause mortality and emergency clinic visits [6, 7]. However, managing the increasing
- 320 population of patients with CIEDs using conventional remote management (periodic
- 321 remote interrogation + alert transmission + in-person outpatient visits) is a major
- 322 clinical and administrative burden [32]. Therefore, by identifying the most effective
- 323 components of RM, follow-up can be optimised without compromising patient

- 324 outcomes. However, CNMA assumes both consistency and additivity. If these
- 325 assumptions are not met, the accuracy of the estimated results will potentially be
- 326 compromised, therefore necessitating careful interpretation.
- 327

328 ETHICS AND DISSEMINATION

- 329 Ethics approval is not required as this study will use existing published data. The results
- 330 will be submitted for publication in a peer-reviewed journal.
- 331 Any significant changes to this protocol will be noted with a description of the change,
- the corresponding rationale, and the date of the amendment when the results are
- 333 reported.
- 334

335 Acknowledgments

336 We would like to thank Editage (www.editage.com) for English-language editing.

337 Data availability statement

338 Data sharing not applicable as no datasets were generated and/or analysed for this study.

339 Funding statement

- 340 This research received no specific grant from any funding agency in the public,
- 341 commercial, or not-for-profit sectors.

342 **Competing interests statement**

343 None declared.

344 Authors' contributions

- 345 TM drafted the protocol. MO, TM, and YS led the development of the review protocol
- and drafted the manuscript. TM and MO contributed to the development of the selection
- 347 criteria, risk of bias assessment strategy and data extraction criteria. TM and MO

- 348 developed the search strategy. HN provided expertise on statistical analysis. MO, NS,
- 349 YS, and TM read all drafts of the manuscript, provided feedback and approved the final
- 350 manuscript.
- 351

352 **REFERENCES**

| 353 | 1. | Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS |
|-----|----|---|
| 354 | | guideline for management of patients with ventricular arrhythmias and the |
| 355 | | prevention of sudden cardiac death: A Report of the American College of |
| 356 | | Cardiology/American Heart Association Task Force on Clinical Practice Guidelines |
| 357 | | and the Heart Rhythm Society. Heart Rhythm 2018;15:e73-189. doi: |
| 358 | | 10.1016/j.hrthm.2017.10.036 |
| 359 | 2. | Authors/Task Force Members: McDonagh TA, Metra M, Adamo M, et al.; ESC |
| 360 | | Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment |
| 361 | | of acute and chronic heart failure: Developed by the Task Force for the diagnosis |
| 362 | | and treatment of acute and chronic heart failure of the European Society of |
| 363 | | Cardiology (ESC). With the special contribution of the Heart Failure Association |
| 364 | | (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. doi: 10.1002/ejhf.2333 |
| 365 | 3. | Slotwiner D, Varma N, Akar JG, et al. HRS Expert Consensus Statement on remote |
| 366 | | interrogation and monitoring for cardiovascular implantable electronic devices. |
| 367 | | Heart Rhythm 2015;12:e69-100. doi: 10.1016/j.hrthm.2015.05.008 |
| 368 | 4. | Ferrick AM, Raj SR, Deneke T, et al. 2023 HRS/EHRA/APHRS/LAHRS expert |
| 369 | | consensus statement on practical management of the remote device clinic. Heart |
| 370 | | Rhythm 2023;20:e92-144. doi: 10.1016/j.hrthm.2023.03.1525 |
| 371 | 5. | Varma N, Epstein AE, Irimpen A, et al.; TRUST Investigators. Efficacy and safety |
| 372 | | of automatic remote monitoring for implantable cardioverter-defibrillator |
| 373 | | follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up |
| 374 | | (TRUST) trial. Circulation 2010;122:325-32. doi: |
| 375 | | 10.1161/CIRCULATIONAHA.110.937409 |

| 376 | 6. | Hindricks G. Taborsky M. Glikson M. et al.: IN-TIME study group. Implant-based |
|-----|-----|--|
| | ~ . | |

- 377 multiparameter telemonitoring of patients with heart failure (IN-TIME): a
- 378 randomised controlled trial. Lancet 2014;384:583–90. doi:
- 379 10.1016/S0140-6736(14)61176-4
- 380 7. Landolina M, Perego GB, Lunati M, et al. Remote monitoring reduces healthcare
- 381 use and improves quality of care in heart failure patients with implantable
- defibrillators: the evolution of management strategies of heart failure patients with
- 383 implantable defibrillators (EVOLVO) study. Circulation 2012;125:2985–92. doi:
- 384 10.1161/CIRCULATIONAHA.111.088971
- 385 8. Boriani G, Da Costa A, Quesada A, et al.; MORE-CARE Study Investigators.
- 386 Effects of remote monitoring on clinical outcomes and use of healthcare resources
- 387 in heart failure patients with biventricular defibrillators: results of the
- 388 MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail
- 389 2017;19:416–25. doi: 10.1002/ejhf.626
- 390 9. Braunschweig F, Anker SD, Proff J, et al. Remote monitoring of implantable
- 391 cardioverter-defibrillators and resynchronization devices to improve patient
- 392 outcomes: dead end or way ahead? Europace 2019;21:846–55. doi:
- 393 10.1093/europace/euz011
- 394 10. Seiler A, Biundo E, Di Bacco M, et al. Clinic Time Required for Remote and
- 395 In-Person Management of Patients With Cardiac Devices: Time and Motion
- 396 Workflow Evaluation. JMIR Cardio 2021;5:e27720. doi: 10.2196/27720
- 397 11. Rücker G, Petropoulou M, Schwarzer G. Network meta-analysis of
- 398 multicomponent interventions. Biom J 2020;62:808–21. doi:
- 399 10.1002/bimj.201800167

| 400 12. Shalliseel L. Mohel D. Clarke M. et al., FRISMA-F Oloub, Fleteneu lebu | 400 | 12. | Shamseer L | . Moher D. | Clarke M. | et al.: | PRISMA-P | Grout | b. Preferred | reporti | ng |
|--|-----|-----|------------|------------|-----------|---------|----------|-------|--------------|---------|----|
|--|-----|-----|------------|------------|-----------|---------|----------|-------|--------------|---------|----|

- 401 items for systematic review and meta-analysis protocols (PRISMA-P) 2015:
- 402 elaboration and explanation. BMJ 2015;350:g7647. doi: 10.1136/bmj.g7647.
- 403 Erratum in: BMJ 2016;354:i4086.
- 404 13. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for
- 405 reporting of systematic reviews incorporating network meta-analyses of health care
- 406 interventions: checklist and explanations. Ann Intern Med 2015;162:777–84. doi:
- 407 10.7326/M14-2385
- 408 14. Chaimani A, Caldwell DM, Li T, et al. Chapter 11: Undertaking network
- 409 meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
- 410 Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions
- 411 version 6.4 (updated August 2023). London: Cochrane, 2023.
- 412 www.training.cochrane.org/handbook
- 413 15. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for
- 414 systematic reviews. Syst Rev 2016;5:210. doi: 10.1186/s13643-016-0384-4
- 415 16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of
- 416 bias in randomised trials. BMJ 2019;366:14898. doi: 10.1136/bmj.14898
- 417 17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
- 418 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2
- 419 18. Noma H, Tanaka S, Matsui S, et al. Quantifying indirect evidence in network
- 420 meta-analysis. Stat Med 2017;36:917–27. doi: 10.1002/sim.7187
- 421 19. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network
- 422 meta-analysis: model estimation using multivariate meta-regression. Res Synth
- 423 Methods 2012;3:111–25. doi: 10.1002/jrsm.1045

- 424 20. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for
- 425 presenting results from multiple-treatment meta-analysis: an overview and tutorial.
- 426 J Clin Epidemiol 2011;64:163–71. doi: 10.1016/j.jclinepi.2010.03.016
- 427 21. Noma H, Maruo K, Tanaka S, et al. NMA: Network Meta-Analysis Based on
- 428 Multivariate Meta-Analysis Models. R Package Version 1.4-1. 2023.
- 429 https://cran.r-project.org/web/packages/NMA/.
- 430 22. Rücker G, Schmitz S, Schwarzer G. Component network meta-analysis compared
- 431 to a matching method in a disconnected network: A case study. Biom J
- 432 2021;63:447–61. doi: 10.1002/bimj.201900339
- 433 23. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis
- 434 works without resampling methods. BMC Med Res Methodol 2015;15:58. doi:
- 435 10.1186/s12874-015-0060-8
- 436 24. Rücker G, Krahn U, König J, et al. netmeta: Network Meta-Analysis using
- 437 Frequentist Methods. R Package Version 2.8-2. 2023.
- 438 https://cran.r-project.org/web/packages/netmeta/index.html
- 439 25. R Core Team. R: A language and environment for statistical computing. R
- 440 Foundation for Statistical Computing, Vienna, Austria. 2021.
- 441 https://www.R-project.org/
- 442 26. RStudio Team. RStudio: Integrated Development for R. RStudio, PBC, Boston,
- 443 MA, USA. 2020. http://www.rstudio.com/.
- 444 27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a
- simple, graphical test. BMJ 1997;315:629–34. doi: 10.1136/bmj.315.7109.629
- 446 28. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an
- 447 emerging consensus on rating quality of evidence and strength of recommendations.

| 448 | BMJ 2008;336:924–6. c | doi: 10.1136/bmj.3 | 39489.470347.AD |
|-----|-----------------------|--------------------|-----------------|
| | / | | |

- 449 29. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence
- 450 from a network meta-analysis. PLoS One 2014;9:e99682. doi:
- 451 10.1371/journal.pone.0099682
- 452 30. Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: Software for
- 453 semiautomated assessment of the confidence in the results of network
- 454 meta-analysis. Campbell Syst Rev 2020;16:e1080. doi: 10.1002/cl2.1080
- 455 31. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach
- 456 for assessing confidence in the results of a network meta-analysis. PLoS Med
- 457 2020;17:e1003082. doi: 10.1371/journal.pmed.1003082
- 458 32. Seiler A, Biundo E, Di Bacco M, et al. Clinic Time Required for Remote and
- 459 In-Person Management of Patients With Cardiac Devices: Time and Motion
- 460 Workflow Evaluation. JMIR Cardio 2021;5:e27720. doi: 10.2196/27720